Don’t want to get conned? Don’t want to be a bagholder? Don’t want to be the mark? Follow the BuyersStrike! Maxims and one’s odds of being suckered go down considerably.
Over the years we’ve often mentioned the Maxims without collecting them in a single page. For the benefit of readers, this page has been created to archive the Maxims and will be updated over time to include them all.
Maxim 1: All reverse mergers are scams. Not some, not a few, not most. All. In one way or another. If the companies were truly legit, they would not be doing reverse mergers. Period. The end. This one rule alone will greatly eliminate your chances of being conned.
Maxim 2: If management pitches the investment as helping bring about a “revolution”, run screaming. One of the great hallmarks of a con is when management, or their shills, pitch investors that they are an active part of building a bright new future. Of course, the investors never realize they are just being passively fleeced in the mundane present.
Maxim 13: Never invest in Christoph Westphal deals. This includes his cronies including Michelle Dipp. If someone was involved in Sirtris in the past, run away. Far far away.
Maxim 19: The FDA does NOT approve studies. Period. Any company that talks about their “FDA Approved” study is attempting to defraud investors. Any analyst who discussed “FDA approved studies” is an untrustworthy tout. Any investor who thinks the FDA approved a certain study is a moron.
Maxim 20: When it comes to drugs and devices, designations like “Fast Track”, “Orphan Drug”, “QIDP”, etc., mean far far less than stock promoters and management teams want you to believe. All these designations mean is that a company has filled out the proper forms and checked the proper boxes. These designations in no way mean the FDA “likes” a drug or device, or “wants” it to be approved, or is a wink, nod, or nudge at all. The benefits, if any, accrue only after NDA/PMA submission or after approval.
The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.